Y-Mabs Therapeutics Inc

NASDAQ:YMAB   3:59:58 PM EDT
39.24
-0.11 (-0.28%)
Products

Y-mAbs’ Nivatrotamab Granted Orphan Drug And Rare Pediatric Disease Designation By FDA

Published: 10/07/2020 13:49 GMT
Y-mAbs Therapeutics, Inc. (YMAB) - Y-mabs’ Nivatrotamab for the Treatment of Patients With Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA.
Y-mabs Therapeutics, Inc - Expect to Submit Ind for Lung Cancer Study During Q4 of 2020.